📰 Maximal Usage Systemic Exposure News
Maximal Usage Systemic Exposure News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Maximal Usage Systemic Exposure. Real-time updates on events, politics, business and more.
October 6, 2023
WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S.
October 6, 2023
This announcement by Arcutis broadens the psoriasis drug’s indication and was done to help simplify management of the skin condition for younger patients as well.
October 6, 2023
Roflumilast is the first topical agent indicated to treat psoriasis in sensitive intertriginous areas of the skin.
October 6, 2023
The FDA has approved Zoryve (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in children ages 6 to 11 years.
October 6, 2023
This marks an expanded indication for the drug, which was first approved for the same indication in July 2022 for individuals aged 12 and older.
December 20, 2022
Roflumilast cream 0.3% was approved for treating psoriasis in adolescents and adults in July.